Why Ocugen, Inc.’s (OCGN) Stock Is Up 5.29%
As of Tuesday, October 06, Ocugen, Inc.’s OCGN share price has surged by 5.29%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Commentary & Analysis
Why Ocugen, Inc.’s (OCGN) Stock Is Up 6.00%
As of Friday, September 25, Ocugen, Inc.’s OCGN share price has surged by 6.00%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Ocugen, Inc.’s (OCGN) Stock Is Down 5.66%
As of Tuesday, September 15, Ocugen, Inc.’s OCGN share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Michael Rose
Why Ocugen, Inc.’s (OCGN) Stock Is Down 8.65%
As of Wednesday, September 09, Ocugen, Inc.’s OCGN share price has dipped by 8.65%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Ocugen, Inc.’s (OCGN) Stock Is Down 13.91%
As of Wednesday, September 09, Ocugen, Inc.’s OCGN share price has dipped by 13.91%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | OCGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $339.1 | $240.6 | 33% |
|
| Shares Out (Mil) | 338.7 | 54.0 | 84% |
|
| Institutional Ownership | 96.5% | 93.1% | 70% |
|
| Float (Mil) | 333.8 | 41.4 | 81% |
|
| Beta | 2.21 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 5,854 | 604 | 93% |
|
| Price Change (52-week) |
(45.1%) | 49.2% | 21% |
|
| Growth | OCGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (25.5%) | (10.1%) | 16% |
|
| EPS (5yr) | 5.9% | 15.8% | 40 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (23.4%) | (15.7%) | 28% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.053) | ($0.237) | ($0.253) | |
| Month Ago EPS | ($0.053) | ($0.270) | ($0.267) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.053) | ($0.223) | ($0.235) | |
| Year/Year Chg | (27.4%) | 4.9% | (2.7%) | |
| Financials | OCGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 5% |
|
| Net Income (TTM) (Mil) | ($82) | ($44) | 13% |
|
| EPS (TTM) | ($0.255) | ($1.600) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($34) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $73 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $347 | $175 | 31% |
|
| Valuation | OCGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.30 | na |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | OCGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (855.3%) | 67.3% | 0% |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (92.0%) | (47.6%) | 6% |
|
| ROE | na | (54.9%) | na |
|
| Liabilities to Assets | 113.3% | 29.3% | 96% |
|
| F-Score | 3 | 3 | 18% |
|
Ocugen, Inc. did not pass any screens on 10/7/2026.
